FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079723940> ?p ?o ?g. }

• W2079723940 abstract "Colistin and tigecycline have both been shown good in vitro activity among multi-drug resistant Acinetobacter baumannii (MDRAB). A comparative study of colistin versus tigecycline for MDRAB pneumonia is lacking.The study enrolled adults with MDRAB pneumonia admitted to intensive care units at a referral medical center during 2009-2010. Since there were no standardized minimum inhibitory concentration (MIC) interpretation criteria of tigecycline against A. baumannii, MIC of tigecycline was not routinely tested at our hospital. During the study periods, MIC of colistin was not routinely tested also. We consider both colistin and tigecycline as definite treatments of MDRAB pneumonia. Patients who received tigecycline were selected as potential controls for those who had received colistin. We performed a propensity score analysis, by considering the criteria of age, gender, underlying diseases, and disease severity, in order to match and equalize potential prognostic factors and severity in the two groups.A total of 294 adults with MDRAB pneumonia were enrolled, including 119 who received colistin and 175 who received tigecycline. We matched 84 adults who received colistin with an equal number of controls who received tigecycline. The two well matched cohorts share similar characteristics: the propensity scores are colistin: 0.37 vs. tigecycline: 0.37, (P = .97); baseline creatinine (1.70 vs. 1.81, P = .50), and the APACHE II score (21.6 vs. 22.0, P = .99). The tigecycline group has an excess mortality of 16.7% (60.7% vs. 44%, 95% confidence interval 0.9% - 32.4%, P = .04). The excess mortality of tigecycline is significant only among those with MIC >2 μg/mL (10/12 vs. 37/84, P = .01), but not for those with MIC ≦ 2 μg/mL (4/10 vs. 37/84, P = .81).Our data disfavors the use of tigecycline-based treatment in treating MDRAB pneumonia when tigecycline and colistin susceptibilities are unknown, since choosing tigecycline-based treatment might result in higher mortality. The excess mortality of tigecycline-based group may be related to higher MIC of tigecycline (> 2 μg/mL). Choosing tigecycline empirically for treating MDRAB pneumonia in the critical setting should be cautious." @default.
• W2079723940 created "2016-06-24" @default.
• W2079723940 creator A5029376678 @default.
• W2079723940 creator A5037686253 @default.
• W2079723940 creator A5037812360 @default.
• W2079723940 creator A5041835555 @default.
• W2079723940 creator A5047717026 @default.
• W2079723940 creator A5049626738 @default.
• W2079723940 creator A5062263322 @default.
• W2079723940 date "2014-02-24" @default.
• W2079723940 modified "2023-10-10" @default.
• W2079723940 title "Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumanniiin a critical setting: a matched cohort analysis" @default.
• W2079723940 cites W1632904338 @default.
• W2079723940 cites W1966481893 @default.
• W2079723940 cites W2002308254 @default.
• W2079723940 cites W2011770881 @default.
• W2079723940 cites W2032644680 @default.
• W2079723940 cites W2036173518 @default.
• W2079723940 cites W2043705783 @default.
• W2079723940 cites W2052608732 @default.
• W2079723940 cites W2054740361 @default.
• W2079723940 cites W2068185639 @default.
• W2079723940 cites W2090570219 @default.
• W2079723940 cites W2096018749 @default.
• W2079723940 cites W2104747240 @default.
• W2079723940 cites W2107994215 @default.
• W2079723940 cites W2118008432 @default.
• W2079723940 cites W2124996394 @default.
• W2079723940 cites W2129711520 @default.
• W2079723940 cites W2132620230 @default.
• W2079723940 cites W2133551776 @default.
• W2079723940 cites W2134744238 @default.
• W2079723940 cites W2135373868 @default.
• W2079723940 cites W2139881333 @default.
• W2079723940 cites W2142343447 @default.
• W2079723940 cites W2146287754 @default.
• W2079723940 cites W2147847713 @default.
• W2079723940 cites W2148134051 @default.
• W2079723940 cites W2148626913 @default.
• W2079723940 cites W2150291618 @default.
• W2079723940 cites W2159435953 @default.
• W2079723940 cites W2163090854 @default.
• W2079723940 cites W4211194064 @default.
• W2079723940 doi "https://doi.org/10.1186/1471-2334-14-102" @default.
• W2079723940 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3936940" @default.
• W2079723940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24564226" @default.
• W2079723940 hasPublicationYear "2014" @default.
• W2079723940 type Work @default.
• W2079723940 sameAs 2079723940 @default.
• W2079723940 citedByCount "101" @default.
• W2079723940 countsByYear W20797239402014 @default.
• W2079723940 countsByYear W20797239402015 @default.
• W2079723940 countsByYear W20797239402016 @default.
• W2079723940 countsByYear W20797239402017 @default.
• W2079723940 countsByYear W20797239402018 @default.
• W2079723940 countsByYear W20797239402019 @default.
• W2079723940 countsByYear W20797239402020 @default.
• W2079723940 countsByYear W20797239402021 @default.
• W2079723940 countsByYear W20797239402022 @default.
• W2079723940 countsByYear W20797239402023 @default.
• W2079723940 crossrefType "journal-article" @default.
• W2079723940 hasAuthorship W2079723940A5029376678 @default.
• W2079723940 hasAuthorship W2079723940A5037686253 @default.
• W2079723940 hasAuthorship W2079723940A5037812360 @default.
• W2079723940 hasAuthorship W2079723940A5041835555 @default.
• W2079723940 hasAuthorship W2079723940A5047717026 @default.
• W2079723940 hasAuthorship W2079723940A5049626738 @default.
• W2079723940 hasAuthorship W2079723940A5062263322 @default.
• W2079723940 hasBestOaLocation W20797239401 @default.
• W2079723940 hasConcept C126322002 @default.
• W2079723940 hasConcept C2776315533 @default.
• W2079723940 hasConcept C2777027569 @default.
• W2079723940 hasConcept C2777637488 @default.
• W2079723940 hasConcept C2777914695 @default.
• W2079723940 hasConcept C2779259085 @default.
• W2079723940 hasConcept C501593827 @default.
• W2079723940 hasConcept C523546767 @default.
• W2079723940 hasConcept C54355233 @default.
• W2079723940 hasConcept C71924100 @default.
• W2079723940 hasConcept C86803240 @default.
• W2079723940 hasConcept C89423630 @default.
• W2079723940 hasConceptScore W2079723940C126322002 @default.
• W2079723940 hasConceptScore W2079723940C2776315533 @default.
• W2079723940 hasConceptScore W2079723940C2777027569 @default.
• W2079723940 hasConceptScore W2079723940C2777637488 @default.
• W2079723940 hasConceptScore W2079723940C2777914695 @default.
• W2079723940 hasConceptScore W2079723940C2779259085 @default.
• W2079723940 hasConceptScore W2079723940C501593827 @default.
• W2079723940 hasConceptScore W2079723940C523546767 @default.
• W2079723940 hasConceptScore W2079723940C54355233 @default.
• W2079723940 hasConceptScore W2079723940C71924100 @default.
• W2079723940 hasConceptScore W2079723940C86803240 @default.
• W2079723940 hasConceptScore W2079723940C89423630 @default.
• W2079723940 hasIssue "1" @default.
• W2079723940 hasLocation W20797239401 @default.
• W2079723940 hasLocation W20797239402 @default.
• W2079723940 hasLocation W20797239403 @default.
• W2079723940 hasLocation W20797239404 @default.
• W2079723940 hasOpenAccess W2079723940 @default.
• W2079723940 hasPrimaryLocation W20797239401 @default.

• next